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Abstract
Background: Laboratory detection of Human papillomavirus (HPV), Chlamydia trachomatis and
Neisseria gonorrhoeae in liquid-based cervicovaginal cytology specimens is now based on
identification of the DNA sequences unique to these infectious agents. However, current
commercial test kits rely on nucleotide probe hybridization to determine DNA sequences, which
may lead to diagnostic errors due to cross-reactivity. The aim of this study was to find a practical
approach to perform automated Sanger DNA sequencing in clinical laboratories for validation of
the DNA tests for these three infectious agents.
Methods: A crude proteinase K digestate of 5% of the cells collected in a liquid-based
cervicovaginal cytology specimen was used for the detection of DNA molecules specific for HPV,
C trachomatis and N gonorrhoeae, and for preparation of materials suitable for direct automated
DNA sequencing. Several sets of commercially available polymerase chain reaction (PCR) primers
were used to prepare nested PCR amplicons for direct DNA sequencing.
Results: Some variants of HPV-16 and HPV-31 were found to share an at least 34-base long
sequence homology downstream of the GP5+ binding site, and all HPV-6 and HPV-11 variants
shared an upstream 34-base sequence including part of the GP5+ primer. Accurate HPV genotyping
frequently required more than 34-bases for sequence alignments to distinguish some of the HPV
genotype variants with closely related sequences in this L1 gene hypervariable region. Using the
automated Sanger DNA sequencing method for parallel comparative studies on split samples and
to retest the residues of samples previously tested positive for C trachomatis and/or for N
gonorrhoeae, we also found false-negative and false-positive results as reported by two commercial
nucleic acid test kits.
Conclusion: Identification of a signature DNA sequence by the automated Sanger method is useful
for validation of HPV genotyping and for molecular testing of C trachomatis and N gonorrhoeae in
liquid-based cervicovaginal Papanicolaou (Pap) cytology specimens for clinical laboratories with
experience in molecular biology to increase the specificity of these DNA-based tests. However,
even a highly specific test for high-risk HPV genotyping may have unacceptably low positive
predictive values for precancer lesion in populations with a low cervical cancer prevalence rate.
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Human papillomavirus (HPV), Chlamydia trachomatis and
Neisseria gonorrhoeae are the causative agents for the three
most common sexually transmitted infections in women.
Newly introduced laboratory diagnostic procedures for
these infectious agents are mostly nucleic acid-based, rely-
ing on detection and identification of a DNA sequence
specific for the infectious agent with or without DNA rep-
lication (amplification) by polymerase chain reaction
(PCR). The tests incorporating PCR amplification in the
procedure, often referred to as nucleic acid amplification
(NAA) tests, are extremely sensitive, capable of detecting a
single copy of target DNA. The result of a DNA-based test
may be validated by identifying a signature sequence of
the target DNA and used for accurate genotyping if HPV
DNA is the target [1-8].
The commercial NAA tests for C trachomatis and N gonor-
rhoeae, all relying on probe hybridization for DNA
sequence determination, are claimed to have a sensitivity
of 85% and a specificity of 97–99%, depending on the
evaluating method chosen for comparison [9]. These tests
tend to generate unacceptably low positive predictive
value (PPV) [10] in low prevalence populations. As a
result, the Centers for Disease Control and Prevention
(CDC) has issued recommendations that an additional
test with different method or with the same method be
performed to confirm a positive NAA test for C trachomatis
and N gonorrhoeae to reduce the possibility of false-posi-
tive results that may have adverse medical, social and psy-
chological impacts on the patient, but also cautions that
such a supplementary test result might itself be falsely
negative [9]. Clinical laboratories often find these tests are
associated with 5.3% of initially C trachomatis-positive
results and 10.7% of initially N gonorrhoeae-positive
results that cannot be confirmed by repeated testing of the
original sample [11].
In the past few years the cost of performing automated
DNA sequencing has decreased considerably. This article
gives a brief summary on the experience of applying this
research tool in HPV genotyping and in the identification
of C trachomatis and N gonorrhoeae DNA in liquid-based
Pap cytology specimens to serve the physicians who want
unequivocal evidence to validate each test result.
Methods
Clinical Materials
The clinical samples used for the HPV study were 2,020
alcohol-preserved liquid-based cervicovaginal Pap cytol-
ogy specimens (ThinPrep or Surepath) routinely submit-
ted by 2 private gynecologists who provided general
obstetric and gynecologic care to local residents in Mil-
ford, Connecticut. Milford has a rural and suburban pop-
ulation of 50,000+, in which 93.6% of the residents are
non-Hispanic whites according to the latest available cen-
sus [12]. The incidence of cervical cancer in the 2,020
patients selected for this study was considered to be repre-
sentative of or below that in the state of Connecticut in
which the cervical cancer rate is 6.8 per 100,000 women
[13]. Publication of the laboratory data with blinded
patient identities was approved by the Milford Hospital
IRB.
The cervicovaginal specimens were collected from women
below age 30 who had a Pap cytology finding of atypical
squamous cells of undetermined significance (ASCUS) or
more severe, and from women 30 years and older in con-
junction with Pap cytology screening when the clinical
specimens were submitted for HPV testing with or with-
out concomitant request for C trachomatis or N gonor-
rhoeae testing (Figure 1). The Pap cytology slides were
screened by a commercial cytology laboratory and all
abnormal slides reviewed by the 2 author pathologists for
final classification.
The cases classified as "ASCUS favoring a reactive process"
under the Bethesda system [14] were grouped with the
normal cases under less than ASCUS (<ASCUS) for the
purpose of analysis in this report. Samples submitted in
the liquid-based Pap cytology vial for C trachomatis and/or
N gonorrhoeae testing were generally from "asymptomatic"
women 15 to 65 years old regardless of Pap cytology find-
ings.
A total of 510 liquid-based Pap cytology specimens were
tested for C trachomatis DNA and a total of 507 tested for
N gonorrhoeae DNA.
Primary and Nested PCR
The cellular debris derived from 5% of a liquid-based Pap
cytology collection was pelleted for primary and nested
PCR amplification of HPV, C trachomatis or N gonorrhoeae
DNA without DNA extraction or purification, as previ-
ously described [15-17].
The residues of 26 endocervical samples which had been
tested positive by the BD Probe Tec™ ET Chlamydia tracho-
matis and Neisseria gonorrhoeae Amplified DNA Assays
(Becton, Dickinson, Sparks, MD) were retested by DNA
sequencing for comparison [16].
All positive nested PCR products were validated by on-
line Basic Local Alignment Search Tool (BLAST) algo-
rithms for final validation of the signature sequence.
The numbers of cases analyzed did not include 38 cases
which were considered inadequate for failed PCR amplifi-
cation of a human β-globin genomic DNA in the samples.Page 2 of 10
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For the samples in which there was a single HPV genotype
in the specimen, genotyping was readily determined with
direct automated DNA sequencing by on-line BLAST
sequence alignment algorithms. An exclusive 100%
"identities" match between the "query" sequence and the
"subject" sequence was required for accurate genotyping.
A 34-base sequence downstream of the GP5+ primer site
excised from the electropherogram of the sample, which is
fully matched with a standard HPV signature sequence
stored in the GenBank validated the HPV genotype, except
for some variants of HPV-16, HPV-31 and HPV-33, for
which BLAST algorithms of a 46–50 base sequence in this
region were needed for unequivocal genotyping (Fig. 2).
When the GP6/MY11 or the HiFi nested PCR primer pair
(catalog #3002, HiFi DNA Tech, LLC, Trumbull, CT) was
used to replace the GP5+/GP6+ primers to prepare a 190–
200 bp nested PCR amplicon for DNA sequencing, an
upstream 30- to 34-base long segment including 11 bases
of the GP5+ primer site, was found to be sufficient to dif-
ferentiate these variants. However, all variants of HPV-6
and HPV-11 share one DNA sequence homology in this
region for 34 bases. Differentiation between these latter
two HPV genotypes depended on finding the four isolated
distinguishing bases further upstream of this sequence
homology (Fig. 3).
Among 2020 specimens, 200 (9.9%) were positive for
HPV DNA, all confirmed by DNA sequencing. A total of
30 genotypes were found, including 12 of the 13 "high-
risk" genotypes targeted by the Digene HC2 assay (Digene
Corporation, Gaithersburg, MD), except HPV-68 which
was detected in this County, but not in this series. Of the
200 HPV-positive specimens, 183 (91.5%) were infected
by a single HPV genotype, all assigned a specific genotype
according to the GenBank sequence database BLAST algo-
Age distribution of 2,020 private patients tested for HPV in Milford, CTFigure 1
Age distribution of 2,020 private patients tested for HPV in Milford, CT.Page 3 of 10
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than one HPV genotype (Additional file 1, Table 1). Since
the patients under age 30 were pre-selected by an abnor-
mal Pap cytology, the HPV positive rate in this group was
about 5 times that observed among the patients age 30 or
older [17].
Of the 200 HPV-positive specimens, 119 (59.5%) were
found to contain at least one of the 13 genotypes of HPV
targeted by the Digene HC2 "high-risk" HPV test kit,
including 3 cases of mixed infections by an HPV-16, HPV-
18 or both, confirmed by specific primer sequencing [18].
Of the HPV-positive specimens, 67 (33.5%) contained
Genotyping distinction between HPV-16 and HPV-31 may need a 50-base sequenceFigure 2
Genotyping distinction between HPV-16 and HPV-31 may need a 50-base sequence. HPV DNA isolated from a 
clinical sample with its partial L1 gene DNA sequence of 50 bases is validated as HPV-16 strain SRB236AK L1 protein (L1) gene 
by the GenBank database. However, HPV-31 isolate N5 and some HPV-33 major capsid protein L1 genes share an identical 34-
base sequence on the upstream (right) segment in this region with this variant of HPV-16. Genotyping error might have 
occurred if only the 34 bases on the right were selected for sequence alignment algorithm.Page 4 of 10
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All HPV-6 and HPV-11 isolates share common L1 DNA sequencesFigure 3
All HPV-6 and HPV-11 isolates share common L1 DNA sequences. Fig. 3 upper HPV-6 DNA isolate from a clinical 
sample with its partial L1 gene DNA sequence of 50 bases is validated as HPV-6 by the GenBak database. Fig. 3 lower HPV-11 
DNA isolate from a clinical sample with its partial L1 gene DNA sequence of 50 bases is validated as HPV-11 isolate Bsb-45 
major capsid protein by the GenBak database. From the left No. 4 base onward (upstream), all known HPV-6 (upper) and 
HPV-11 (lower) isolates share a 34-base sequence. In this "hypervariable region" which is generally used for HPV L1 genotyp-
ing, differentiation between HPV-6 and HPV-11 depends on identification of a four-base difference upstream of these 34 com-
mon bases, but before another sequence homogeny starting with CCCCA.
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HC2 kit.
Four (4) cases of HSIL (high-grade squamous epithelial
lesion) were found in this series, constituting 0.2% of the
specimens submitted for HPV testing, namely in 2% of the
specimens with a positive result for HPV. Two of these
HSILs were associated with a single HPV-16, one with an
HPV-39, and one with an HPV-69 infection. A LSIL (low-
grade squamous epithelial lesion) was found in 29 of the
200 specimens with a positive result for HPV (14.5%).
The 123 cases classified as "<ASCUS" included the speci-
mens with a normal Pap cytology from women age 30 or
older, and those specimens from younger women whose
Pap cytology was classified as "ASCUS favoring a reactive
process".
A 40-base signature sequence of the cryptic plasmid DNA
specific for the C trachomatis species was used as a signa-
ture sequence (Fig. 4). A visualized nested PCR product
finally proved to be C trachomatis cryptic plasmid DNA by
sequencing in the absence of a concomitant primary PCR
band represented detection of a "low-positive" amount of
species-specific DNA equivalent to that extracted from 1
to 2 × 106 elementary bodies in one sample collection.
The positive cases with a concomitant visible primary PCR
band were classified as "high-positive" [16].
A 40-base DNA sequence on the electropherogram was
found to be sufficient for validation of the signature
sequence of gonococcal opa genes (Fig. 5). A "High-posi-
tive" result, indicated by a concomitant visible primary
PCR product, represented detection of a DNA content
extracted from at least 2 × 105 cells of N gonorrhoeae in one
sample collection. Positive cases detected by nested PCR
only were classified as "low positive" [16].
Of the clinical specimens collected from 146 patients, 2 in
paired samples for parallel assays by PCR/DNA sequenc-
ing and by the GEN-PROBE® PACE® 2C test were found to
be "high-positive" for C trachomatis cryptic plasmid DNA
by nested PCR/DNA sequencing and also positive by the
Species-specific signature sequence of Chlamydia trachomatis cryptid plasmid DNAFigure 4
Species-specific signature sequence of Chlamydia trachomatis cryptid plasmid DNA. The signature sequence for 
Chlamydia trachomatis is almost constant between various clinical isolates. Any 40 bases selected from the electropherogram of 
this DNA sequence of the positive nested PCR product gives a "100% identities" match for a cryptic plasmid gene.Page 6 of 10
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Another four paired specimens (4/146) were found to be
"low-positive" for C trachomatis cryptic plasmid DNA by
nested PCR/DNA sequencing, but negative by GEN-
PROBE® assays. All remaining 140 samples were negative
for C trachomatis by both methods.
All 146 paired samples submitted for Gen-Probe assays
were found to be negative for N gonorrhoeae. But 5 of
the146 liquid-based Pap cytology specimens (5/146) sub-
mitted for nested PCR/DNA sequencing were found to be
"low-positive" for gonococcal opa gene DNA by nested
PCR/DNA sequencing.
The residues of 26 endocervical samples previously tested
positive by the BD Probe Tec™ ET Chlamydia trachomatis
and Neisseria gonorrhoeae Amplified DNA Assays (Becton,
Dickinson and Co., Sparks, MD) were retested for com-
parison, following a protocol previously published [16].
The results showed that 8 of the 14 cases reported to be
positive for C trachomatis by the BD Probe Tec assays were
found to be "high-positive", 5 of the 14 to be "low-posi-
tive", and 1 of the 14 to be negative for C trachomatis cryp-
tic plasmid DNA. Of the 12 cases reported to be positive
for N gonorrhoeae by the BD Probe Tec assays, 8 were
found to be "high-positive", and 4 to be "low-positive" for
gonococcal gene DNA. In addition, nested PCR/DNA
sequencing showed that one of the N gonorrhoeae "high-
positive" cases also contained a "high-positive" C tracho-
matis cryptic plasmid DNA which was in a mixed infection
and missed by the BD Probe Tec test. Thus, the nested
PCR/DNA sequencing retesting of the residues of 26 spec-
imens reported to be positive by a commercial NAA test
kit found 1 false positive and 1 false negative result.
Using the nested PCR/DNA sequencing assays on samples
collected in liquid-based Pap cytology vials, we found 2
cases of "high-positive" (0.39%) and 5 cases of "low-pos-
itive" (0.98%) C trachomatis infection in 510 consecu-
tively received routine specimens collected from 2 private
Species-specific sequences of Neisseria gonorrhoeae opa genesFigure 5
Species-specific sequences of Neisseria gonorrhoeae opa genes. The electropherogram of gonococcal opa genes in this 
signature sequence region always illustrates a mixture of sequences generated by multiple opa gene templates. This particular 
tracing shows a clear base calling of 50 bases by the computer. However, in many cases only 40 bases on the right are selected 
for analysis because overlapping peaks tend to appear toward the left of the tracing due to co-migration of nucleotides having 
one molecular weight, but carrying different dye-labeled terminators due to the fact that gonococcal opa gene nested PCR 
products are not homogenous and may range from 127 to 130 base pairs in size.Page 7 of 10
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mens were collected from a patient presenting with a
recent onset of lower abdominal pain and from a patient
whose male sexual partner was recently diagnosed with
acute chlamydial urethritis. During the same period, we
found 10 "low-positive" (1.97%) and no "high-positive"
(0%) N gonorrhoeae cases in 507 consecutively received
liquid-based Pap cytology specimens.
Discussion
Unlike the traditional methods based on bacterial culture,
the highly sensitive commercial NAA tests for detecting C
trachomatis and N gonorrhoeae lack a 100% analytical spe-
cificity [9]. No commercial test kits available in the USA
for specific genotyping of the 13 generally recognized
high-risk HPV genotypes.
Several probe-based test kits for HPV genotyping have
been evaluated [19,20] for information on accurate HPV
genotyping may play an important role in following per-
sistent HPV infections [21-24]. However, when the GP5+/
GP6+ PCR products with a hypervariable DNA sequence
are targeted for developing genotyping methods, the DNA
probe designed for one HPV type may cross-react with
other non-target types despite the presence of four base
mismatches in each pair [25]. Cross-reaction is a major
challenge in distinguishing some of the individual geno-
types of HPV based on the hybridization technology [26].
As we have demonstrated in this report, certain variants of
HPV-16 and HPV-31 share a sequence homology of at
least 34 bases downstream of the GP5+ site (Fig. 2). All
variants of HPV-6 and HPV-11 share a sequence homol-
ogy of 34 bases upstream of this region (Fig. 3). Increasing
the specificity of the currently available HPV test has been
suggested as a potential approach to reduce the number of
excessive colposcopic procedures in the USA [27].
Using a modified automated Sanger DNA sequencing for
HPV genotyping after nested PCR amplification, we found
a 9.9% HPV positive rate in the specimens collected from
2 private gynecology offices primarily serving the local res-
idents with a population 50,000+ in the rural and subur-
ban United States. The true HPV positive rate in this
general women population is probably lower because all
patients under 30 who had a much higher HPV infection
rate were pre-selected with an abnormal Pap cytology
before being accepted for HPV testing. In this population,
HPV-16 is the most prevalent single genotype found, con-
stituting 19.0% of the HPV isolates, followed by HPV-52,
-18 and -59 in decreasing order (Additional file 1, Table
1).
Of the 2,020 cervicovaginal specimens, 5.9% (119 cases)
contained at least 1 "high-risk" HPV genotype while only
0.2% (4 cases) showed an HSIL in cytology (Additional
file 1, Table 1). Of the 4 HSIL cases, 2 were associated with
an HPV-16, 1 with an HPV-39 and 1 with an HPV-69.
HPV-69 is not included in the Digene HC2 "high risk"
group, but has been shown to be of high risk in HIV-
infected patients [28]. No invasive cancer was detected.
If HSIL cytology were used as the endpoint for clinical
evaluation, the clinical specificity for HSIL of one-occa-
sion "high-risk" HPV positivity by the DNA sequencing
method would be (2020-119)/(2020-4) = 94%; the clini-
cal sensitivity would be 4/4 = 100%; the negative predic-
tive value (2020-119)/(2020-119 + 0) = 100%; and the
positive predictive value (ppv) would be 4/(4+115) =
3.4%. This extremely low ppv of an HPV DNA sequencing
assay, even with a high 94% clinical specificity, empha-
sizes the reality that using one-occasion HPV testing to
formulate guidelines for management triage is bound to
generate excessive colposcopic procedures [27] in popula-
tions with a low cervical cancer prevalence.
In this series, even the most "high-risk" HPV-16 infection
is rarely associated with cellular dysplasia. Of the 38 spec-
imens positive for HPV-16 DNA, 2 cases (5.3%) show a
HSIL as mentioned above, 2 a LSIL and 5 an ASCUS cytol-
ogy. The remaining 29 HPV-16 isolates (76.3%) were
associated with a reactive or a normal Pap cytology (Addi-
tional file 1, Table 1). It seems to be more appropriate to
use this virology test for referring patients with an ambig-
uous Pap cytology result and persistent high-risk HPV
infection to colposcopy [29].
Since the introduction of the liquid-based Pap cytology
testing into clinical practice, there has been an increasing
demand for performing Pap cytology, HPV detection,
HPV genotyping, and the detection of C trachomatis and N
gonorrhoeae with one specimen collected in a single con-
tainer.
In clinical practice, most of the cervicovaginal samples
from patients presenting with symptomatic or acute gono-
coccal infections are collected by swabs which are usually
submitted for bacteriological culture and Gram staining.
NAA tests for N gonorrhoeae in liquid-based Pap cytology
specimens are usually requested when the patients present
with subclinical or asymptomatic gonococcal infections.
Because the traditional cell culture method for C trachom-
atis detection is no longer readily available, requests for C
trachomatis nucleic acid tests in the liquid-based speci-
mens are often for both symptomatic and asymptomatic
patients. As a result, we have seen mostly "low-positive"
results for N gonorrhoeae opa gene DNA in the liquid-based
Pap cytology specimens with a positive rate of 2.0%, but
both "low-positive" and "high positive" cases for C tracho-
matis cryptic plasmid DNA in the same period with a pos-
itive rate of 1.4%. There seems to be more asymptomaticPage 8 of 10
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in this community. However, since the present series is
small and the patients studied are highly selective, these
numbers do no represent infection rates in women living
in this population.
Accurate nucleic acid detection of C trachomatis and N gon-
orrhoeae in clinical specimens is challenging. Most com-
mercial NAA tests target a DNA segment of the cryptic
plasmid DNA for C trachomatis detection and the sensitiv-
ity of the tests has been high. However, recently a variant
of C trachomatis with a 377-bp deletion in the cryptic plas-
mid (GenBank accession no. EF 121757) has emerged,
causing probe failures for certain commercial kits which
target this deleted segment for their real time PCR assays
[30,31]. In our procedure, we choose a species-specific
sequence about 3000 bases downstream of the 377-bp
deletion site for amplification to avoid the potential fail-
ure caused by the 377-bp deletion.
Nucleic acid detection of N gonorrhoeae is more complex.
All commercial gonococcal NAA tests, including those tar-
geting the cppB, opa and 16S genes and the porA pseudog-
ene for amplification [32-38], are associated with a less
than desirable degree of sensitivity and specificity. The
great capacity of N gonorrhoeae for genetic variation and
recombination is the major cause of this technical com-
plexity. Members of the Neisseria species are capable of
taking up exogenous DNA throughout their entire life
cycle, causing gonococci acquiring commensal Neisseria
DNA sequences, and vice versa [39,40]. Genetic recombi-
nation between gonococci can take place in vitro and in
vivo [41], turning any given DNA segment into a potential
moving target for detection. The cppB-based PCR assays
are known to have generated false-negative results in pop-
ulations infected by gonococci lacking the cppB gene
(non-PAU- subtype) [42,43] For our procedure, we have
chosen a DNA strand of 40 bases in the promoter region
of the gonococcal opa genes for target amplification and as
the signature sequence. This short DNA sequence appears
to be highly conserved and constant for distinguishing
itself from those of other non-gonococcal neisserial opa
genes, including those of Neisseria meningitidis [16].
Conclusion
DNA sequencing can be used for accurate HPV genotyping
and accurate molecular identification of C trachomatis and
N gonorrhoeae in clinical laboratories with molecular biol-
ogy experience to increase the specificity of these microbi-
ology tests. However, an HPV test even with a high
virology specificity may still have a very low positive pre-
dictive value if a precancer lesion is used as the endpoint
for evaluation in a population with low cervical cancer
prevalence.
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